7 commentaries on the 2017 diagnostic marketplace | Diaceutics

7 commentaries on the 2017 diagnostic marketplace

April 26th, 2017

In regular Pharma Readiness reports Diaceutics analyses the global marketplace for diagnostic integration, summarizing the year that’s gone and making predictions for the months ahead. But given our unique position as thought leaders in the space, with inside knowledge of the diagnostic, pharmaceutical and laboratory industries, we have gone into more detail in the Ebook, Pharma Readiness for Diagnostic Integration 2017: Opinion pieces on the precision medicine and diagnostic marketplace in 2017 and beyond.

Written by Peter Keeling, CEO of Diaceutics and Jeff Waldron, Executive Director of PMConnective.org, these commentaries discuss the current and future state of the diagnostic and precision medicine marketplaces at a time when industrial, clinical and research activity is driving us with acceleration towards a long-promised transformation of healthcare delivery. Subjects include disruption in precision medicine, getting things right with PD-L1, segmentation and lack of integration.

As a discussion of the way our healthcare and business models are heading it is sure to raise some surprising and even controversial points. And if you want to delve deeper into diagnostic issues, our other Ebooks should provide plenty of thought-provoking content.

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
View all publications
Facebook
Twitter
YouTube
LinkedIn